NASDAQ · Health care

Anavex Life Sciences Corp. (AVXL)

It posted a net loss of $13M. At June 30, 2026 it held $118.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 28, 2026.

What Anavex Life Sciences Corp. does

Anavex Life Sciences Corp. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AVXL.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$51.4M	-$46.4M	-$0.54	n/a
2024	n/a	-$52.9M	-$43M	-$0.52	n/a
2023	n/a	-$55.8M	-$47.5M	-$0.60	n/a
2022	n/a	-$51M	-$48M	-$0.62	n/a
2021	n/a	-$42M	-$37.9M	-$0.54	n/a
2020	n/a	-$31.1M	-$26.3M	-$0.45	n/a

Latest SEC filings

What Anavex Life Sciences Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 21, 2026
Form DFAN14A filing DFAN14A
September 18, 2026
Form DFAN14A filing DFAN14A
September 17, 2026
Form DFAN14A filing DFAN14A
September 15, 2026
Additional proxy material DEFA14A
September 15, 2026
Form DFAN14A filing DFAN14A
September 14, 2026
Additional proxy material DEFA14A
September 10, 2026
Form DFAN14A filing DFAN14A
September 10, 2026
Form DFAN14A filing DFAN14A
September 9, 2026
Form DFAN14A filing DFAN14A
September 9, 2026
Other event 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on May 14, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about AVXL

What does Anavex Life Sciences Corp. do?

Anavex Life Sciences Corp. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AVXL.

Is Anavex Life Sciences Corp. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $13M.

When did Anavex Life Sciences Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form DFAN14A filing from September 21, 2026.

Similar companies

AMGN

Amgen Inc

GILD

Gilead Sciences, Inc.

Neurocrine Biosciences Inc

EXEL

Exelixis, Inc.

Follow AVXL

Get an email when Anavex Life Sciences Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow AVXL: get an email when it files

Where the numbers come from

Financial figures are the values Anavex Life Sciences Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.